Gene Editing Market Research Report 2025-2029 - Biotech Leaders Drive Innovation as Gene Editing Becomes Key to Sustainable Solutions
Gene editing technologies like CRISPR are revolutionizing biotechnology, expanding from medical applications to diverse industries. Initially used for altering genes in human cells to cure previously uncurable diseases, they are now paving the way for rapid growth and new industrial applications. Discover the emerging opportunities, near and long-term expectations, and growth potential through comprehensive research that empowers you as an expert in your field. Complimentary additional data is available.
Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Gene Editing Markets 2025-2029 by Application, Technology, Place, Industry and Product with Executive & Consultant Guides" report has been added to ResearchAndMarkets.com's offering.
This comprehensive view of the gene editing landscape highlights the technology's potential to drive transformative change. As breakthroughs become more frequent, businesses need to stay informed about the latest trends and projections. Those equipped with thorough market insights are poised to leverage these technologies effectively, ensuring competitive advantages in their respective fields.
Gene Editing is moving from strength to strength. CRISPR and similar tools are finding new uses in every area of biotechnology. It started with Medical applications by changing genes in living human cells. Uncurable diseases have already being cured. More are on the way.
The market for gene editing tools is witnessing a surge, with rapid growth driven by technological advances. These tools are broadening their reach beyond healthcare, offering groundbreaking possibilities in agriculture, biofuel production, and more. Major players in the biotechnology industry are spearheading research to develop innovative applications, ensuring continual market evolution.
Industry experts indicate that the gene editing industry is set to continue its rapid expansion. Companies and researchers are actively investigating diverse opportunities in areas such as crop improvement, pest control, and sustainable resource management. These developments position gene editing as a cornerstone technology, promising significant impacts on global food security and sustainable practices.
The gene editing market is becoming increasingly sophisticated, with new applications and technologies emerging regularly. As demand for more precise and efficient biotechnological solutions grows, the sector continues to attract substantial investment. Key players are focusing on research and development, strengthening their market positions, and pushing forward innovations to meet both current needs and future challenges.
Key Topics Covered:
1 Market Guides1.1 Strategic Situation Analysis1.2 Guide for Executives, Marketing, Sales and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors2 Introduction and Market Definition2.1 Methodology2.1.1 Methodology2.1.2 Sources2.1.3 Authors2.2 What is Gene Editing?2.3 The CRISPR Example2.3.1 What is CRISPR?2.3.2 The CRISPR Family2.4 Chromosomes, Genes and Epigenetics2.4.1 Chromosomes2.4.2 Genes2.4.3 Epigenetics2.5 Market Definition2.5.1 Revenue Market Size2.6 Perspective: Healthcare Spending2.6.1 Global Healthcare Spending2.6.2 Spending on Healthcare and Pharmaceuticals2.6.3 Spending on Diagnostics2.6.4 Important Role of Insurance for Medical Services3 Market Structure3.1 Market Structure Therapeutics3.1.1 Research and Development (R&D) Companies3.1.2 Biotechnology Companies3.1.3 Generic Drug Manufacturers3.1.4 Big Pharmaceuticals3.1.5 Contract Research Organizations (CROs)3.1.6 Contract Manufacturing Organizations (CMOs)3.1.7 Specialty Pharmaceutical Companies3.1.8 Pharmaceutical Distributors3.1.9 Retail Pharmacies3.1.10 Wholesalers3.1.11 Online Pharmacies3.1.12 Health Technology Companies3.1.13 Pharmacy Benefit Managers (PBMs)3.1.14 Clinical Laboratories3.1.15 Medical Device Companies3.1.16 Regulatory Bodies3.2 Market Structure Diagnostics3.2.1 Academic Research Lab3.2.2 Diagnostic Test Developer3.2.3 Instrumentation Supplier3.2.4 Chemical/Reagent Supplier3.2.5 Pathology Supplier3.2.6 Independent Clinical Laboratory3.2.7 Public National/regional Laboratory3.2.8 Hospital Laboratory3.2.9 Physicians Office Lab (POLS)3.2.10 Audit Body3.2.11 Certification Body4 Market Trends4.1 Factors Driving Growth4.1.1 Cell Therapy4.1.2 Gene Therapy4.1.3 The New Agriculture4.1.4 Genetics and Cell Metabolism4.2 Factors Limiting Growth4.2.1 The Cost Curve4.2.2 Time and Trials4.2.3 The Price Barrier5 Recent Developments in Gene Editing5.1 Recent Developments - Importance and How to Use This Section5.1.1 Importance of These Developments5.1.2 How to Use This Section5.2 CRISPR tool allows for remote-controlled gene-editing5.3 CRISPR Making Sweeter Tomatoes5.4 Researchers Create gene-edited prawns5.5 Gene Editing Corrects Cystic Fibrosis5.6 CRISPR gene editing to change healthcare?5.7 CrisprBits Collaborates With MolBio Diagnostics5.8 Sherlock Bioscience to Launch Free AI-Based Operating System5.9 Sherlock Biosciences to Acquire Sense Biodetection5.10 CRISPR Enzyme Discovery Opens New Applications5.11 Sherlock Biosciences Adds Ambient Amplification to Toolkit5.12 Rice University Adapts CRISPR Enzyme5.13 Princeton Group Develops Cas13 Assay for Point-of-Care Use5.14 Proof Dx Plans Infectious Disease, Oncology Tests for CRISPR-Based POC System5.15 Sherlock Biosciences Raises $80M5.16 Broad Institute Considers CRISPR Respiratory Panels to Replace PCR5.17 Medix Biochemica Acquires MyPols Biotec5.18 Mammoth Biosciences High-Throughput CRISPR-Based COVID Test Gets EUA5.19 Genome Diagnostics Makes €1M Investment in Scope Biosciences5.20 CRISPR Test Could be used for Asymptomatic Screening5.21 Mammoth Biosciences, Agilent to Comarket CRISPR-Based SARS-CoV-2 Test5.22 Pandemic Accelerates Development of CRISPR Diagnostics5.23 ERS Genomics Licenses CRISPR Patents to Vivlion5.24 Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test5.25 ERS Genomics, FASMAC to Commercialize CRISPR-Cas95.26 The Nobel Prize in Chemistry 2020 - CRISPR Wins6 Key Companies6.1 10x Genomics, Inc.6.2 4D Molecular Therapeutics6.3 Abeona Therapeutics6.4 Acrigen Biosciences6.5 Adarx Pharmaceuticals6.6 Adverum Biotechnologies6.7 Affini-T Therapeutics6.8 Agilent6.9 Arbor Biotechnologies6.10 Arcturus Therapeutics6.11 Axxam6.12 Beam Therapeutics6.13 Beckman Coulter Diagnostics (Danaher)6.14 Becton, Dickinson and Company6.15 Binx Health6.16 bioMerieux Diagnostics6.17 Bio-Rad Laboratories, Inc.6.18 Bluebird Bio6.19 Caribou Biosciences6.20 Cell Microsystems6.21 Cellenion (BICO)6.22 Century Therapeutics6.23 Chroma Medicine6.24 Creative Biogene6.25 Crispr Therapeutics6.26 Editas Medicine6.27 ERS Genomics6.28 FASMAC6.29 Genscript Biotech6.30 Illumina6.31 Inscripta6.32 Intellia Therapeutics6.33 J&J Innovative Medicine6.34 Locus Biosciences6.35 Mammoth Biosciences6.36 Metagenomi6.37 Myllia Biotechnology6.38 Namocell6.39 NRGene6.40 Poseida Therapeutics6.41 Precision Biosciences6.42 Prime Medicine6.43 Proof Diagnostics6.44 Regeneron Pharmaceuticals6.45 Revvity6.46 Roche Diagnostics6.47 Sherlock Biosciences6.48 Thermo Fisher Scientific6.49 Twist Bioscience6.50 Verve Therapeutics6.51 Vivlion6.52 Wave Life Science7 The Global Market for Gene Editing7.1 Global Market Overview by Country7.2 Global Market by Application - Overview7.3 Global Market Technology - Overview7.4 Global Market Type - Overview7.5 Global Market Industry - Overview7.6 Global Market Product - Overview8 Gene Editing Markets - By Application8.1 Cell Line8.2 Plant8.3 Animal8.4 Cell Therapy8.5 Gene Therapy8.6 Diagnostics8.7 Research9 Global Gene Editing Markets - by Technology9.1 Crispr9.2 Talens9.3 ZFN9.4 Meganuclease10 Gene Editing Markets - by Place10.1 In Vivo10.2 Ex Vivo10.3 In Vitro11 Gene Editing Markets - by Industry11.1 Pharma11.2 Clinical11.3 Academic11.4 Contract12 Global Gene Editing Markets - by Product12.1 Instruments12.2 Cells12.3 Reagents13 Appendices13.1 United States Medicare System: laboratory Fees Schedule13.2 The Most Used IVD Assays13.3 The Highest Grossing Assays13.4 The Whole Genome Sequence of SARS-CoV-213.5 Global Listing of Sequencing Establishments - Location & Contacts
For more information about this report visit https://www.researchandmarkets.com/r/ktk8g
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
2 hours ago
- Business Upturn
XRP News: Vaultro Finance Presale on XRP Is Set to End in 7 Days, Already Sold Out 72% of Its Allocation — Join $VLT Presale Now
By GlobeNewswire Published on June 21, 2025, 23:50 IST SINGAPORE, June 21, 2025 (GLOBE NEWSWIRE) — Vaultro Finance has smashed through another milestone, announcing today that its $VLT token presale has sold over 70% of its total allocation, with just seven days left before the sale ends. In under a week, commitments have soared from 62% to 72%, underscoring an extraordinary rush among investors to secure positions in Vaultro's fully decentralized index fund protocol on the XRP Ledger. Participate in $VLT Presale Vaultro Finance delivers an on-chain investing breakthrough. Its dashboard at replaces complex fund-building steps with a simple, intuitive interface. Users can browse thematic portfolios, spanning artificial intelligence tokens, capital-preserving stablecoins, emerging DeFi projects, and leading XRPL assets—then customize allocations and monitor performance in real time. A built-in staking module allows $VLT holders to lock their tokens and earn passive rewards proportional to protocol usage. All transactions settle on chain via XRPL Hooks and Escrow, ensuring speed, security, and full transparency. Join $VLT Presale Now At the heart of Vaultro's ecosystem is the $VLT token itself. Early backers recognize that $VLT unlocks every protocol feature. Token ownership grants the exclusive right to create and launch custom index funds, vote on fund listings and protocol upgrades, and enjoy reduced fees when minting, rebalancing, or withdrawing fund positions. Staking $VLT not only generates yield for long-term supporters but also helps secure network liquidity and governance. $VLT Presale Details: Price: 1 XRP = 8 VLT Listing Price: 1 XRP = 6.15 VLT Hardcap: 60,000 XRP (72% already sold) $VLT Presale Portal: With over 70% of tokens now claimed and exactly seven days left, the window to participate is closing fast. Prospective buyers will need an XRP-native wallet and must set up a $VLT trustline. A minimum contribution of 200 XRP ensures broad accessibility, while the official presale portal at remains open. Don't miss your final chance to claim $VLT at presale pricing. Join the rush now and help shape the future of on-chain index fund investing on the XRP Ledger. For more details on Vaultro Finance and the $VLT presale visit; Website Join $VLT Presale X fka Twitter Telegram Community Whitepaper Blog Channel Contact:Lee Wang [email protected] Disclaimer: This is a paid post and is provided by Vaultro Finance. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
2 hours ago
- Business Upturn
ZA Miner Launches Free Cloud Mining App Amid Rising Crypto Adoption in 2025
London, UK, June 21, 2025 (GLOBE NEWSWIRE) — As global interest in cryptocurrencies continues to climb, ZA Miner has announced the official launch of its free cloud mining app, giving users the ability to earn crypto passively, without the cost or complexity of traditional mining setups. This marks a significant milestone in ZA Miner's mission to democratize crypto access worldwide. The new mobile application enables both beginner and experienced users to mine digital assets like Bitcoin (BTC), Ethereum (ETH), and Dogecoin (DOGE) directly from the cloud. With no hardware needed and no upfront fees, users can start mining immediately after registering, and even receive a free $100 trial mining contract upon signup. A Seamless Gateway into Crypto Mining ZA Miner's app stands out for its simplicity. Once installed, users can choose from a range of mining plans based on their budget and desired contract length, with options starting as low as $100. Earnings are calculated and distributed daily in USDT, and the platform handles everything from GPU management to energy optimization. Key features include: Free $100 cloud mining trial for new users for new users Instant registration — only an email is needed — only an email is needed Daily payouts in stablecoin (USDT) in stablecoin (USDT) Tiered referral rewards , allowing users to earn commission from their network , allowing users to earn commission from their network No maintenance or setup costs Meeting the Demand for Accessible Crypto Tools The launch of the app comes at a time when crypto mining demand is surging, driven by rising token prices and growing public interest in passive income strategies. Yet, traditional mining still poses significant entry barriers for many, including high hardware costs, technical complexity, and environmental concerns. ZA Miner addresses all of these issues with a cloud-based infrastructure, backed by secure, globally distributed data centers powered in part by renewable energy. The app offers a secure and transparent mining experience, removing technical roadblocks for anyone looking to benefit from the crypto economy. Built for Global Accessibility With active users in over 180 countries, ZA Miner has steadily grown its reputation as a trusted cloud mining provider since its launch. The mobile app is available in multiple languages and supports users from both crypto-savvy and underserved markets. The company's referral system also allows users to boost their earnings by inviting friends, with commissions paid on multiple levels, enhancing user engagement and reach. How to Get Started Download the ZA Miner app from the official website Register with an email address Claim your free $100 DOGE mining trial Choose a mining contract and begin earning daily payouts Withdraw profits or reinvest anytime About ZA Miner ZA Miner is a UK-based cloud mining provider offering simple, secure, and sustainable crypto mining solutions for individuals worldwide. With a focus on accessibility, clean energy, and automated passive income. Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
